CRISPR Therapeutics AG

Most Recent

  • CRISPR Therapeutics logo over DNA sequence
    Company & Industry Overviews

    Why CSRP Stock Is a Good Buy Despite Losses

    By Rachel Curry
  • Woman reviewing data
    Company & Industry Overviews

    The Best Gene-Editing ETF for Your Portfolio in 2021

    By Rachel Curry
  • uploads///microbiology _
    Company & Industry Overviews

    Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday

    On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.

    By Daniel Collins
  • uploads///Sangamo
    Company & Industry Overviews

    A Financial Overview of Sangamo Therapeutics in December 2018

    In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Taking Stock of Vertex’s Performance

    Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.

    By Kenneth Smith
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///flasks _
    Company & Industry Overviews

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.

    By Daniel Collins
  • uploads///blood _
    Company & Industry Overviews

    How Is Vertex Pharmaceuticals Positioned in October?

    Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.

    By Kenneth Smith
  • uploads///Vertex
    Company & Industry Overviews

    Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space

    Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter.

    By Daniel Collins
  • uploads///Intellia
    Company & Industry Overviews

    A Financial Overview of Intellia Therapeutics in September

    In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million.

    By Daniel Collins
  • uploads///virus _
    Company & Industry Overviews

    Analysts Are Mostly Positive on Intellia Therapeutics This Month

    On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24.

    By Daniel Collins
  • uploads///CRSP
    Company & Industry Overviews

    How CRISPR Therapeutics Is Positioned in September

    CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///molecule
    Company & Industry Overviews

    CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent

    On June 19, the co-owners of intellectual property associated with CRISPR-Cas9 genome editing technology were granted a US patent.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Why Editas Medicine Fell 7.8% on Monday

    On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.

    By Mike Benson
  • uploads///puzzle _
    Company & Industry Overviews

    Crispr Therapeutics Stock Fell 12.6% on June 11

    On June 11, Crispr Therapeutics (CRSP) stock fell 12.6% to $59.57 over concerns that the CRISPR-CAS9 Gene Therapy causes cancer.

    By Mike Benson
  • uploads///cells _
    Company & Industry Overviews

    CRISPR Stock Has Seen Soild Growth in the Last 12 Months

    CRISPR Therapeutics has risen 24% between May 11 and May 17.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.